Press Releases

First broadly available, standardized Health Risk Assessment in veterinary medicine FLORHAM PARK, N.J., December 1, 2014 – Zoetis is pleased to announce that the American Animal Hospital Association (AAHA) has selected the company’s Pet Wellness Report® (PWR) as AAHA’s exclusive Preferred Business Provider for Health Risk Assessments in veterinary medicine. AAHA accredited hospitals are traditionally on the forefront of advancing new approaches to medical care for companion animals. The endorsement lends credibility to this innovative communication tool, which further enhances veterinary wellness efforts. The PWR is the first broadly available, standardized Health Risk Assessment for use in veterinary medicine. The report is designed to identify modifiable lifestyle risks, provide clues to early warning signs of disease, and facilitate client communication and education. PWR encourages greater pet owner involvement in the wellness care of their pet. “Preferred Business Provider status ...

Zoetis joined a new initiative working to advance the standards of small animal veterinary care across Africa. The African Small Companion Animal Network (AFSCAN) aims to facilitate the creation of a sustainable network of companion animal veterinarians, associations and specialist groups in sub-Saharan Africa. This network will facilitate the formation of new Small Animal Veterinary Associations (SAVAs) across the continent. Read the full press release here . ...

A Total of $100,000 Available to Fund Feline Pain, Osteoarthritis, Joint Health and Kidney Disease Research FLORHAM PARK, N.J. - February 26, 2014 - The Winn Feline Foundation, in a unique funding opportunity sponsored by Zoetis Inc., announced today a call for proposals to address the assessment of pain, osteoarthritis, joint health and kidney disease in cats. A total of $100,000 is available to fund proposals of sufficient scientific merit, relevance and potential to impact feline health. Consideration will be given to proposals investigating novel biomarkers for assessing acute or chronic adaptive pain and maladaptive (i.e., neuropathic or functional) pain in cats. Biomarkers for assessing osteoarthritis progression are also of interest. Scientifically sound projects that investigate the cause and progression of osteoarthritis in cats will also be considered, regardless of biomarker assessment.  Additionally, because methods for early detection and progression of feline chronic ...

First Janus Kinase Inhibitor Approved for Veterinary Use in Europe PARIS, FRANCE, January 29, 2014 – Zoetis Inc. announced today the launch of Apoquel® (oclacitinib maleate), a novel therapy indicated for the treatment of pruritus (itching) associated with canine allergic dermatitis and the clinical manifestations of atopic dermatitis. Veterinarians across Europe now have a first-in-class treatment choice that targets the itch of allergic skin conditions in dogs. Apoquel is the first Janus Kinase (JAK) inhibitor approved for veterinary use. It provides rapid and sustained relief of pruritus and improves skin lesions without the side-effects associated with commonly-used therapies, such as glucocorticoids. Canine pruritus is among the most frequent complaints of pet owners, affecting about one in six dogs whose owners seek veterinary help. About half of all itchy dogs will have an underlying allergic skin condition for which Apoquel would be indicated. Pascal Prélaud, a dermatology ...

First Veterinary Janus kinase Inhibitor Targets the Itch of Allergic Skin Conditions at Its Source FLORHAM PARK, N.J. – Jan. 20, 2014 – Zoetis Inc. today announced that APOQUEL® (oclacitinib tablet) is now available to veterinarians in the United States for the control of pruritus, or itching, associated with allergic dermatitis and the control of atopic dermatitis in dogs at least 12 months of age. With APOQUEL, veterinarians now have a first-in-class treatment choice that targets the itch of allergic skin conditions at its source. Canine itching is among the most frequent complaints of pet owners, affecting about one in six dogs whose owners seek veterinary help. About half of all itchy dogs will have an underlying allergic skin condition where APOQUEL would be indicated. “When a dog develops an itch related to an allergy, it can be life-disrupting for the dog and the entire family. After gaining five years of experience with APOQUEL through my involvement in clinical trials, I’ve ...